NL-OMON41496已完成不适用
Sirolimus Eluting Angioplasty Balloon for In-Stent REstenosis (SABRE) Trial - SABRE
Caliber Therapeutics, Inc.0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Inclusion Criteria
- •1.Age > 18 years
- •2.Patient is willing to provide informed written consent and comply with follow-up visits and testing schedule.
- •3.Patients eligible and indicated for in-stent PCI with documented evidence of ischemia by invasive or non-invasive diagnostic method.
- •4.Patients who are eligible for coronary revascularization (angioplasty and/or CABG)
- •5.Female patients of child bearing potential must have a negative pregnancy test within one week before treatment and must use adequate contraception.
- •6.Previous history of native coronary bare metal stenting * 1 month or drug eluting stenting * 3 months.;Angiographic Inclusion Criteria
- •7.Target vessel with Reference Vessel Diameter (RVD) from 2.5 to 3.5 mm by coronary angiography.
- •8.Target lesion is in a native coronary artery with previous bare metal stent or drug eluting stent. Target lesion with overlapping stents is acceptable if lesion is within stent. (Balloon should be sized so that it does not extend more than 2 mm from the edge of the stent.)
- •9.Inclusion permitted following successful pre-dilatation of target ISR lesion with remaining residual stenosis of * 40%.
- •o No flow limiting dissection requiring additional procedures or implantation of a stent
- •o Lesion continues to meet inclusion criteria of length and diameter
- •o No uncontrollable spasm
- •10.Target lesion length < 21mm by coronary angiograph (note: Virtue should extend at least 2mm beyond pre-dilatation balloon length to avoid geographical miss).
- •11.Guide wire is able to cross lesion and be placed in distal vessel prior to enrollment.
- •12.Inclusion permitted after successful treatment of 1 non-study, low risk lesion in a single non-study vessel.
排除标准
- •Exclusion Criteria
- •1.Patient enrolled in another study with any investigational drug or device, who have not reached primary endpoint.
- •2.Patients scheduled for a major surgical intervention within 7 months of enrollment of the study.
- •3.Patients with recent (* 72 hours) unstable coronary syndromes (e.g. ACS or STEMI * ST elevated myocardial infarction (MI)). If patient has had NSTEMI prior to 72 hrs. and enzyme level is decreasing within 72 hrs. (at least 2 measurements showing decreasing trend) and patient meets AHA risk guidelines for PCI procedure (low risk) then patient is eligible.
- •4.Patients with a contraindication to an emergency coronary bypass surgery.
- •5.Any individual who refuses a blood transfusion if needed.
- •6.Patients with serum creatinine > 2.0 mg/dL or > 177umol/L.
- •7.Patients with platelet count < 50,000 cells/mm³.
- •8.Patients who had a cerebral stroke < 6 months prior to the index procedure.
- •9.Documented LVEF (Ejection Fraction) < 30% tested within 4 weeks prior to index procedure.
- •10.Patients with any known allergy, hypersensitivity or intolerance to anti-platelet therapy (for example ASA, clopidogrel or ticlopidine) and sirolimus.
- •11.Any known allergy to contrast medium that cannot be pre-treated.
- •12.Women who are pregnant or breastfeeding.;Angiographic Exclusion Criteria
- •13.More than 1 target lesion within the target vessel.
- •14.Presence of any non-target lesion within the target vessel.
- •15.Failure to successfully treat the non-target vessel (non-target vessel must be treated prior to the target vessel)
- •16.Aorto-ostial lesion (Left Main or Ostial Right Coronary Artery).
- •17.Target lesion distance from the ostium of LAD/LCX is < 5 mm.
- •18.Target lesion is located in either a venous or arterial graft.
- •19.Lesions at edge of stent requiring dilatation > 2 mm beyond stent.
- •20.Angiographic evidence of thrombus at the target site.
- •21.Acute total occlusions of non-target lesion or > 40% stenosis of target lesion following pre-dilatation.
- •22.Lesion requiring additional implant or results in flow limiting dissection following pre-dilatation.
- •23.Bifurcation lesions (lesions < 5 mm from a side branch vessel with > 2 mm diameter.)
研究者
相似试验
招募中
不适用
Sirolimus-coated balloon versus drug-eluting stent in native coronary vesselsNL-OMON54209Fondazione Ricerca e Innovazione Cardiovascolare, No profit organization315
尚未招募
不适用
Sirolimus-coated balloon versus drug-eluting stent in native coronary vesselsNL-OMON22515Fondazione Ricerca e Innovazione Cardiovascolare ETS1,130
撤回
不适用
Combo Bio-Engineered Sirolimus Eluting Stent Placement Long-Term Healing Pattern Assessment by Optical Coherence Tomographyincidence of intracoronary thrombi and late lossneointimal morphologyStrut coverage (binary and thickness)strut malapposition10011082NL-OMON41146Academisch Medisch Centrum40
撤回
不适用
Drug eluting BALLoon angioplasty to prime bifuRcation lesiOns for stenting: a prOspective randoMized trialNL-OMON33521Sint Antonius Ziekenhuis200
Unknown
不适用
Scoring-Balloon Angioplasty and Sirolimus-Eluting Balloon Angioplasty for the Treatment of Diffuse, Small Vessel Coronary Artery Disease (SCA-DEB Study)Coronary Artery DiseaseNCT06197022University National Heart Hospital106